Technology

Krieger Scientific’s founder and CEO discusses how various factors, such as siloed systems and misuse of AI, may be responsible for the increase of warning letters from FDA.

Such enterprises will be defined not only by breakthrough therapies but also by agile leadership, AI-enabled transformation and patient-centered operating models that accelerate innovation into real-world impact.

Veeva's president of commercial strategy discusses how agentic AI is surfacing the treatment barriers and HCP insights that traditional call reporting was never built to capture.

Inizio Engage is expanding its Global Medical Information platform with Connected Insights to convert the more than one million scientific interactions its teams handle annually into actionable intelligence.

In this episode, Ron Lanton argues that healthcare's next constraint isn't capital or technology but rather people.

Mike Faddoul, Partner, Audit & Assurance, Crowe, makes the case that gross-to-net accounting deserves the same pre-launch rigor as commercial strategy.

AI adoption in pharma drops sharply in the domains that matter most for discovery.

In today's Pharmaceutical Executive Daily, Invivyd's chief scientific officer discusses a platform designed to predict future viral variants ahead of time, Bristol Myers Squibb expands its AI compute infrastructure with Nvidia to build what it calls the most powerful AI factory in life sciences, and FDA clears Consano Bio's IND for a non-opioid biologic targeting chronic sciatica.

Bristol Myers Squibb is deploying Nvidia's DGX SuperPOD with Vera Rubin NVL72 systems to build what it claims is the most powerful AI computing infrastructure in life sciences.

Robert Allen, Ph.D., Chief Scientific Officer, outlines how the company's Invymab platform uses viral surveillance and predictive modeling to design monoclonal antibodies against likely future variants rather than current strains.

AI can generate words that sound like empathy, but it cannot offer the understanding that a real person can.

Ken Banta and Craig Tooman on why the best leaders win by asking better questions — not just chasing more data — and what that means for drug development, funding and AI in the years ahead.

Insilico Medicine and Bora Pharmaceuticals entered a strategic alliance to pair Insilico's AI drug discovery platform with Bora's development and manufacturing infrastructure.

Insilico Medicine has deepened its partnership with China Medical System Holdings with a second CNS-focused collaboration in three months, pairing Insilico's PandaOmics-identified mechanism with CMS's clinical and commercial infrastructure in a deal worth up to $177 million in milestones.

The two companies will work together to advance the development of small molecule discovery at the research center.

Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of concentrated AI bets — not scattered pilots — can better drive real transformation without losing sight of governance, culture or patients.

Aprecia’s president and COO discusses the impact 3D printing technology is having on drug development, along with the benefits and challenges of being a company that is 100-percent US-based for its manufacturing.

Insilico will use its AI platform for the drug development process, while SK handles the late-stage and commercialization processes.

Novavax’s EVP of corporate affairs and head of its Sweden division discusses new vaccine technologies, such as its adjuvant matrix technology, are bringing new players into the space.

With clinical trial data exploding to nearly 6 million datapoints, eClinical Solutions' CEO and Co-founder, Raj Indupuri makes the case for price transparency and a measurable ROI in clinical data technology.

The driving force behind Lilly’s Medicine Foundry on transforming the discovery-to-production handoff.

Special Guest Op-Ed: The time is now to elevate manufacturing and supply to a defining pillar of life sciences innovation.

AI-powered data analytics has evolved from a supporting function into the backbone of modern brand strategy and decision-making.

Chai Discovery has licensed its generative AI drug discovery platform to Pfizer, giving the company early access to its next-generation Chai-3 model and a custom model trained on Pfizer's own data.

Alnylam Pharmaceuticals has partnered with Inceptive to apply generative AI to siRNA design, pairing Inceptive's biology-trained models with Alnylam's two decades of proprietary RNAi data to accelerate candidate discovery.